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Inhibitors	of	nicotinamide	N-methyltransferase	designed	to	mimic	
the	methylation	reaction	transition	state		
Matthijs	J.	van	Harena,	Rebecca	Taiga,	Jilles	Kuppensa,	Javier	Sastre	Torañoa,	Ed	E.	Moret,a	Richard	
B.	Parsons,b	Davide	Sartinic,	Monica	Emanuellic	and	Nathaniel	I.	Martina*	
Nicotinamide	 N-methyltransferase	 (NNMT)	 is	 an	 enzyme	 that	 catalyses	 the	 methylation	 of	 nicotinamide	 to	 form	 N’-
methylnicotinamide.	Both	NNMT	and	its	methylated	product	have	recently	been	linked	to	a	variety	of	diseases,	suggesting	
a	role	for	the	enzyme	as	a	therapeutic	target	beyond	its	previously	ascribed	metabolic	function	in	detoxification.	We	here	
describe	 the	 systematic	 development	of	NNMT	 inhibitors	 derived	 from	 the	 structures	of	 the	 substrates	 involved	 in	 the	
methylation	 reaction.	 By	 covalently	 linking	 fragments	 of	 the	 NNMT	 substrates	 a	 diverse	 library	 of	 bisubstrate-like	
compounds	was	prepared.	The	ability	of	these	compounds	to	inhibit	NNMT	was	evaluated	providing	valuable	insights	into	
the	 structural	 tolerances	of	 the	enzyme	active	 site.	These	 studies	 led	 to	 the	 identification	of	new	NNMT	 inhibitors	 that	
mimic	 the	 transition	 state	 of	 the	 methylation	 reaction	 and	 inhibit	 the	 enzyme	 with	 activity	 on	 par	 with	 established	
methyltransferase	inhibitors.	
Introduction	
Nicotinamide	N-methyltransferase	 (NNMT)	 is	 an	 enzyme	 that	
transfers	 a	 methyl	 group	 from	 S-adenosyl-L-methionine	
(AdoMet)	 to	 nicotinamide	 (NA)	 forming	 N’-methyl-
nicotinamide	(MNA)	and	S-adenosyl-L-homocysteine	(AdoHcy)	
(Fig.	 1).	 The	 enzyme	 has	 gained	 much	 interest	 in	 the	 last	
decade	 because	 of	 its	 involvement	 in	 a	 variety	 of	 diseases.	
Whereas	 30	 years	 ago,	 the	 enzyme	 was	 thought	 to	 function	
exclusively	 in	 detoxification	 and	 metabolic	 pathways,	 it	 has	
now	become	clear	that	the	enzyme	has	far	more	complex	roles	
in	 both	 healthy	 and	 disease	 states.	 In	many	 types	 of	 cancer,	
NNMT	is	overexpressed	and	it	has	the	potential	as	a	biomarker	
for	 gastric,	 oral,	 renal	 and	 lung	 cancers.1–4	 In	 this	 regard,	 the	
overexpression	 of	 NNMT	 has	 recently	 been	 shown	 to	 cause	
AdoMet	 depletion	 in	 cancer	 cells.5	 Other	 studies	 have	
suggested	 a	 role	 for	 NNMT	 as	 a	 cytoprotective	 agent	 in	
Parkinson’s	disease6–8	while	other	findings	point	to	a	potential	
link	 between	 MNA	 and	 lifespan	 regulation.9	 In	 addition,	 the	
upregulation	 of	 NNMT	 is	 observed	 in	 a	 range	 of	 metabolic	
disorders	 including	 diabetes	 and	 obesity.10–12	 Despite	 its	
implication	 in	 many	 disease	 states,	 very	 few	 inhibitors	 of	
NNMT	have	been	described	to	date.13,14	Therefore,	we	set	out	
to	 develop	 inhibitors	 of	 NNMT	 based	 on	 a	 bi-substrate	
transition	state	mimic	approach.	The	recently	reported	NNMT	
crystal	structure	reveals	the	interactions	of	the	substrates	with	
the	active	site	residues	(Fig.	2).15	The	active	site	can	be	roughly	
divided	 into	 three	 binding	 pockets:	 one	 for	 the	 adenosine	
group	 (A),	 one	 for	 the	 amino	 acid	 moiety	 (B)	 and	 one	 for	
nicotinamide	 unit	 (C).	 In	 designing	 the	 inhibitors	 here	
described	 we	 focused	 on	 the	 structural	 elements	 of	 the	
substrates	implicated	in	the	transition	state	of	the	methylation	
reaction.	
By	 linking	 fragments	 of	 the	 NNMT	 substrates	 known	 to	
interact	with	the	different	active	site	pockets,	bisubstrate-like	
inhibitors	 were	 obtained	 and	 their	 inhibitory	 activity	
evaluated.	The	first	series	of	 inhibitors	examined	were	simple	
N-alkylated	 nicotinamide	 analogues.	 In	 a	 second	 series,	 we	
coupled	 the	 adenosine	moiety	 to	 the	 nicotinamide	 ring	 via	 a	
range	 of	 spacers.	 In	 a	 third	 approach,	 we	 omitted	 the	
adenosine	 group	 and	 instead	 coupled	 nicotinamide	 to	 an	
amino	acid	moiety	again	with	a	variety	of	spacers.	Finally,	we	
also	 synthesized	 a	 “trivalent”	 compound	 comprising	 the	
Figure	 1.	Methylation	 of	 nicotinamide	 (NA)	 by	 NNMT	 using	 S-adenosyl-L-methionine	
(AdoMet)	as	the	methyl	donor,	forming	N’-methylnicotinamide	(MNA)	and	S-adenosyl-
L-homocysteine	(AdoHcy)	
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nicotinamide,	adenosine	and	amino	acid	moieties	with	the	aim	
of	simultaneously	interacting	with	all	three	binding	pockets.	To	
assess	NNMT	inhibition,	we	used	an	assay	recently	developed	
in	 our	 group.16	 This	 assay	 employs	 Ultra	 High	 Performance	
(UHP)	 Hydrophilic	 Liquid	 Interaction	 Chromatography	 (HILIC)	
Quadrupole	 Time-Of-Flight	Mass	 Spectrometry	 (QTOF-MS)	 to	
rapidly	 and	 efficiently	 measure	 NNMT	 activity.	 Using	 this	
method,	 we	 previously	 determined	 the	 IC50	 values	 for	 the	
general	 methyltransferase	 inhibitors	 sinefungin	 and	 AdoHcy	
and	here	demonstrate	that	it	can	be	used	for	the	evaluation	of	
new	NNMT	 inhibitors.	 In	 the	 sections	 below	we	 describe	 the	
synthesis	 of	 the	 different	 NNMT	 inhibitors	 designed	 and	
discuss	their	inhibitory	activity.	
Results	and	Discussion	
The	 inhibitors	 described	 in	 the	 present	 study	 all	 contain	 a	
nicotinamide	 mimic	 and	 were	 designed	 to	 approximate	 the	
NNMT	 transition	 state.	 The	different	 inhibitors	here	explored	
each	build	upon	the	nicotinamide	mimic	which	was	elaborated	
to	include	structural	elements	of	the	adenosine	and/or	amino	
acid	moieties	of	the	AdoMet	cofactor.	The	NNMT	inhibition	of	
all	 compounds	 prepared	 was	 first	 assessed	 at	 a	 fixed	
concentration	 of	 250	 µM.	 In	 cases	 where	 at	 least	 50%	
inhibition	 was	 detected	 at	 this	 concentration	 full	 inhibition	
curves	 were	 measured	 in	 triplicate	 to	 determine	 the	
corresponding	IC50	values.	
The	first	set	of	compounds	studied	were	prepared	directly	
from	nicotinamide,	which	was	N-alkylated	with	 ethyl,	 propyl,	
isopropyl,	 allyl,	 butyl,	 cyclopropyl,	 cyclobutyl,	 cyclopentyl,	
cyclohexyl	and	benzyl-groups	(Scheme	1).	For	the	synthesis	of	
compounds	 2a-i,	 we	 developed	 a	 convenient	 microwave-
assisted	 alkylation	 procedure	 followed	 by	 straightforward	
purification	of	 the	 alkylated	products	 via	 precipitation.	When	
testing	 the	 positively	 charged	 N-alkylated	 nicotinamides	 as	
NNMT	 inhibitors,	we	 found	 that	N-alkylation	 of	 nicotinamide	
with	any	group	bigger	than	a	methyl	group	-	as	present	in	MNA	
-	 lead	 to	 inactive	compounds.	While	MNA	was	 found	 to	have	
an	 IC50	 value	 of	 24.6	 ±	 3.2	 µM	 (Table	 1),	 none	 of	 the	 other	
alkylated	compounds	exhibited	NNMT	inhibition	at	250	µM.		
The	next	series	of	NNMT	inhibitors	pursued	were	based	on	
a	bisubstrate	strategy.	This	approach	is	similar	to	that	recently	
described	 by	 our	 group	 in	 preparing	 inhibitors	 of	 protein	
arginine	 N-methyltransferases17.	 To	 this	 end,	 an	 adenosine	
moiety	was	 coupled	 to	 a	 nicotinamide	mimicking	 group	 via	 a	
series	 of	 different	 linkers	 (Scheme	 2).	 Unlike	 the	 positively	
charged	 N-alkylated	 compounds	 prepared	 in	 the	 first	 series	
(Scheme	 1),	 the	 bisubstrates	 were	 prepared	 as	 neutral	
compounds	wherein	 the	 pyridine	 of	 nicotinamide	 is	 replaced	
with	a	benzene	core.	 In	examining	 the	NNMT	transition	state	
model	(Fig.	2),	 it	appears	that	the	spacing	between	the	ribose	
group	 of	 the	 adenosine	 moiety	 and	 the	 nitrogen	 of	
nicotinamide	is	3	atoms.	We	therefore	synthesized	three-atom	
spaced	conjugates	of	adenosine	and	benzamide	via	N-,	O-	and	
S-linkages	resulting	in	compounds	9-11.		
Intermediate	 compound	 6	 was	 prepared	 via	 reductive	
amination	 of	 free	 amine	 3	 with	 methyl	 3-formylbenzoate,	
followed	by	microwave-assisted	amidation	of	the	methyl	ester	
using	concentrated	ammonium	hydroxide	in	methanol.	A	final	
deprotection	 step	 using	 TFA	 and	 water	 and	 subsequent	
purification	 by	 preparative	 HPLC	 gave	 compound	 9.	 For	 the	
preparation	 of	 thioether	 bisubstrate	 analogue	 10,	
intermediate	 compound	 7	 was	 first	 prepared	 via	 a	 one-pot	
deprotection	 of	 S-acetylated	 thiol	 4	 followed	 by	 direct	
alkylation	 with	 methyl-3-bromomethylbenzoate.	 Subsequent	
amidation,	 deprotection,	 and	 purification	 yielded	 compound	
10.	 For	 the	 synthesis	 of	 oxy-ether	 linked	 conjugate	 11	 the	
exocyclic	 adenine	 amine	 was	 dibenzoylated	 to	 avoid	
overalkylation	 by	 methyl-3-bromomethylbenzoate	 under	 the	
strongly	 basic	 conditions	 necessary	 for	 ether	 formation.	
Following	O-alkylation,	intermediate	8	was	amidated	followed	
by	 deprotection	 and	 purification	 to	 yield	 11.	 Somewhat	
surprisingly,	 bisubstrate	 analogues	 9-11	 showed	 very	 little	
NNMT	 inhibition	 at	 a	 concentration	 of	 250	 µM.	 This	 lack	 of	
inhibition	 may	 be	 explained	 by	 both	 the	 omission	 of	 the	
pyridine	 nitrogen	 as	well	 as	 the	 absence	 of	 interactions	with	
the	 amino	 acid	 binding	 pocket.	 This	 explanation	 is	 supported	
by	 the	 significantly	 reduced	 enzymatic	 activity	 previously	
reported	 for	 the	 Y20A	 mutant	 of	 NNMT.15	 As	 seen	 in	 the	
Figure	 2.	 Schematic	 overview	 of	 the	 methylation	 reaction	 transition	 state	 of	 NNMT	
showing	the	structures	of	substrates	AdoMet	in	blue	and	nicotinamide	in	red	and	their	
interactions	 with	 the	 active	 site	 residues.	 The	 active	 site	 can	 be	 divided	 into	 three	
binding	pockets:	adenosine	pocket	A;	amino	acid	pocket	B	and	nicotinamide	pocket	C.	
Scheme	1.	Synthesis	of	alkylated	nicotinamides	2a-i	via	microwave-assisted	coupling	of	
alkyl	 bromides	 or	 iodides.	 Reagents	 and	 conditions:	 a)	 alkyl	 iodide	 or	 alkyl	 bromide,	
CH3CN,	µW,	140°C,	1.5h,	29-92%.	
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NNMT	 crystal	 structure	 (Fig.	 2),	 the	 active	 site	 Tyr20	 residue	
coordinates	both	the	nicotinamide	moiety	and	the	carbonyl	of	
the	AdoMet	amino	acid	group.	
To	 separately	 assess	 the	 role	 of	 the	 AdoMet	 amino	 acid	
group,	 bisubstrate	 inhibitors	 comprised	 of	 a	 nicotinamide	
mimic	 linked	 to	 a	 carboxylic	 acid	 or	 amino	 acid	moiety	were	
next	prepared	(Schemes	3-5).	A	range	of	different	 linkers	was	
used	 in	 preparing	 these	 conjugates.	 Based	 on	 the	 transition	
state	model,	the	spacing	between	the	carboxylic	acid	unit	and	
the	 aromatic	 ring	 of	 the	 nicotinamide	 unit	 is	 6	 atoms.	 We	
therefore	 prepared	 analogues	 containing	 5-,	 6-,	 and	 7-atom	
linkers	 to	 investigate	 the	optimal	 spacing	 for	 inhibitor	design.	
To	examine	the	binding	requirements	for	 interaction	with	the	
NNMT	 amino	 acid	 binding	 pocket,	 compounds	 bearing	 a	
terminal	 carboxylic	 acid,	 a	 primary	 amide,	 or	 an	 amino	 acid	
moiety	 were	 prepared.	 In	 preparing	 compounds	 18-25	
(Scheme	 3A)	 a	 Sonogashira	 cross-coupling	 reaction	was	 used	
to	 couple	 fragment	 pairs.	 Conveniently,	 we	 found	 that	 the	
cross-coupling	 reaction	 did	 not	 require	 protecting	 groups	 on	
either	the	amide	or	carboxyl	functionalities	which	significantly	
simplified	 access	 to	 the	 target	 compounds.	 Furthermore,	
formation	of	the	intermediate	alkyne	provided	the	opportunity	
to	also	 investigate	 the	effect	of	altered	 rigidity	and	geometry	
in	 the	 linkers.	 Reduction	 of	 the	 alkyne	 intermediates	 12-17	
using	 standard	 hydrogenation	 conditions	 led	 to	 clean	
formation	 of	 the	 fully	 saturated	 species	 18-23.	 Partial	
reduction	was	also	 investigated	to	provide	both	the	E-	and	Z-
alkene	 variants	 derived	 from	 the	 6-carbon	 spaced	 compound	
14.	To	this	end	the	Z-alkene	24	was	prepared	using	the	Lindlar	
catalyst	 while	 the	 E-alkene	 25	 was	 accessed	 using	
Cp*RuCl(cod)	 as	 a	 catalyst.18	 In	 both	 cases,	 the	 E/Z	 ratio	was	
greater	 than	 95%	 and	 the	 desired	 products	 were	 well	
separable	from	both	the	alkyne	starting	material	and	any	over-
reduced	 alkane	 side-product.	 Compounds	 27	 and	 28	 were	
synthesized	 in	 similar	 fashion	 starting	 from	 Boc-protected	
homo-propargylglycine	 (Scheme	 3B).	 The	 most	 active	
compounds	 in	 this	 series	 were	 the	 6-	 and	 7-carbon	 spaced	
compounds	14,	16,	20,	and	22	containing	a	terminal	carboxylic	
acid	 (see	 Table	 1).	 The	 exception	 is	 compound	 23,	 which	
contains	 a	 terminal	 amide.	 The	 lack	 of	 inhibitory	 activity	 for	
compounds	 24-28	 is	 rather	 surprising	 given	 their	 structural	
similarity	to	the	active	analogues.		
In	 addition	 to	 the	 carbon	 linked	 compounds,	 we	 also	
prepared	analogues	containing	hetero-atom	spacers	consisting	
of	either	nitrogen	or	 sulphur	 (Schemes	4	and	5).	 Synthesis	of	
the	 amine	 linked	 conjugate	 35	 was	 achieved	 via	 a	 reductive	
amination	 approach	 similar	 to	 that	 used	 for	 the	 synthesis	 of	
compound	 9.	 As	 illustrated	 in	 Scheme	 4,	 the	 protected	
diaminobutyric	 acid	 building	 block	 33	 was	 coupled	 with	
methyl-3-formylbenzoate	 to	 yield	 intermediate	34	which	was	
subsequently	 deprotected	 and	 amidated	 using	 the	 same	
microwave-assisted	 procedure	 described	 for	 the	 preparation	
of	 9-11.	 Preparation	 of	 the	 thioether	 spaced	 conjugate	 41	
(Scheme	 5)	 required	 access	 to	 thioacetate	 38	 which	 was	
generated	 via	 an	 unusual	 but	 effective	 method	 using	
potassium	thioacetate	absorbed	on	silica	gel.19	Deprotection	of	
38	 by	 treatment	 with	 potassium	 carbonate	 was	 followed	 by	
coupling	 with	 bromide	 3620	 to	 form	 protected	 thioether	 40.	
Final	compound	41	was	obtained	using	the	general	procedures	
for	deprotection	and	amidation.	
To	complete	the	library	of	bisubstrate-based	inhibitors,	the	
ternary	 compound	 45	 was	 also	 designed	 with	 the	 aim	 of	
simultaneously	interacting	with	all	three	binding	pockets	of	the	
NNMT	 active	 site	 (Scheme	 6).	 To	 this	 end	 the	 previously	
prepared	 compound	 6	 (Scheme	 2)	 was	 coupled	 to	 aldehyde	
4321	 via	 reductive	 amination	 to	 give	 44,	 which	 was	
subsequently	 deprotected	 and	 amidated	 to	 yield	 45.	 In	
performing	 the	 NNMT	 inhibition	 assays	 a	 number	 of	
compounds	known	to	 inhibit	the	enzyme	were	also	evaluated	
Scheme	2.	Synthesis	of	the	adenosine-nicotinamide	conjugates	9-11.	Reagents	and	
conditions:	a)	methyl	3-formylbenzoate,	Na(OAc)3BH,	4A	molsieves,	DCE,	rt,	16h,	60%;	
b)	methyl	3-bromomethylbenzoate,	NaOCH3,	MeOH,	Ar(g),	-20°C	to	rt,	16h,	75%;	c)	
methyl	3-bromomethylbenzoate,	NaH	55%	dispersion	in	mineral	oil,	DMF,	rt,	16h,	32%;	
d)	25%	NH3	(aq),	MeOH,	µW,	130°C,	3h;	e)	TFA,	DCM,	rt,	1h.	
Scheme	 3.	 A)	 Synthesis	 of	 alkynes	 12-17	 via	 Sonogashira	 cross-coupling	 and	
subsequent	 reduction	 of	 the	 alkynes	 to	 alkenes	 24	 and	 25	 and	 alkanes	 18-23.	 B)	
Synthesis	 of	 alkyne	27	 and	 its	 corresponding	 alkane	 28.	Reagents	 and	 conditions:	 a)	
Pd(PPh3)2Cl2,	CuI,	Et3N,	THF,	50°C,	4h,	27-89%;	b)	10%	Pd/C,	H2,	MeOH,	rt,	1h,	62-88%;	
c)	 Lindlar	 catalyst,	H2,	MeOH,	 rt,	 3h,	85%;	d)	Cp*RuCl(cod),	H2,	DCM,	rt,	16h,	60%;	e)	
TFA,	DCM,	rt,	1h.	
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Table	1.	IC50	values	for	NNMT	inhibitors	evaluated.a		
Compound	 IC50	in	µM	 Compound	 IC50	in	µM	
sinefungin	 17.0	±	3.4	 18	 >	250	
MNA	 24.6	±	3.2	 19	 >	250	
AdoHcy	 75.4	±	6.3	 20	 69.0	±	14.8	
4MeMNA	 95.9	±	14.1	 21	 >	250	
norharmane	 115.3	±	20.6	 22	 148.1	±	36.3	
2a-i	 >	250	 23	 30.8	±	3.6	
9	 >	250	 24	 >	250	
10	 >	250	 25	 >	250	
11	 >	250	 26	 >	250	
12	 >	250	 27	 >	250	
13	 >	250	 28	 >	250	
14	 189.7	±	30.0	 35	 >	250	
15	 >	250	 41	 >	250	
16	 57.8	±	4.2	 45	 29.2	±	4.0	
17	 >	250	 	 	
a	Assays	performed	in	triplicate	on	at	least	six	different	inhibitor	concentrations.	
Standard	errors	reported.	
as	reference	compounds	(Fig.	3).	As	summarized	in	Table	1,	the	
general	 methyltransferase	 inhibitors	 AdoHcy	 (IC50	 75.4	 ±	 6.3	
µM)	and	sinefungin	(17.0	±	3.4	µM)	display	clear	 inhibition	of	
NNMT.	 Also	 included	 was	 the	 NNMT	 product	 inhibitor	 MNA	
(IC50	 24.6	 ±	 3.2	 µM).	 Given	 that	 MNA	 itself	 is	 the	 analyte	
detected	 in	the	standard	NNMT	activity	assay,	 the	alternative	
NNMT	 substrate	 4-methyl-nicotinamide	 (4MeNA)	 was	 in	 this	
case	 used.	 In	 this	 regard,	 we	 also	 evaluated	 4-methyl-N’-
methyl-nicotinamide	 (4MeMNA)	 as	 an	 additional	 NNMT	
product	 inhibitor	 (IC50	 95.9	 ±	 14.1	 µM),	 using	 the	 standard	
assay	 conditions.	 We	 also	 studied	 the	 ability	 of	 the	
polyaromatic	 compound	 norharmane	 to	 inhibit	 NNMT.	
Previous	studies	revealed	norharmane	to	be	a	weak	substrate	
for	NNMT	with	 a	KM	 value	of	 90	µM,	 significantly	 lower	 than	
that	of	 the	native	substrate	NA	 (KM	200	µM),	but	with	a	very	
low	turnover	rate.22	We	were	therefore	interested	in	assessing	
whether	 such	 a	 strong	 binding,	 slowly	 converted	 NNMT	
substrate	 might	 in	 fact	 act	 as	 an	 inhibitor	 by	 occupying	 the	
NNMT	 active	 site.16,22	 Indeed,	 it	 was	 found	 that	 norharmane	
inhibits	NNMT	with	an	IC50	of	115.3	±	20.6	µM.	The	 low	KM	is	
offset	 by	 a	 diminished	 turnover	 rate	 giving	 norharmane	 the	
ability	to	occupy	the	NNMT	active	site	and	effectively	block	the	
methylation	of	nicotinamide.		
Among	 the	 newly	 synthesized	 compounds	 tested,	 only	
those	 containing	 structural	 elements	 derived	 from	 both	 the	
nicotinamide	 unit	 and	 the	 amino	 acid	 moiety	 of	 AdoMet	
resulted	 in	 appreciable	 inhibition	 (>50%	 at	 250	 µM).	
Interestingly,	 compounds	9-11	wherein	 the	adenosine	moiety	
was	 linked	 to	 a	 benzamide	 unit	 designed	 to	 mimic	
nicotinamide,	showed	no	significant	 inhibition.	Rather,	 linking	
of	the	benzamide	unit	to	a	simple	carboxylate	as	in	14,	16,	20,	
22,	 and	 23	 (amide	 not	 carboxylate)	 gave	 much	 better	
inhibition	and	provide	 key	 insights	 into	 the	preferred	 spacing	
and	 rigidity	 of	 the	 linker	 used	 to	 connect	 the	 respective	
bisubstrate-mimicking	functionalities.	The	results	indicate	that	
the	 optimal	 spacing	 is	 6-7	 atoms.	 Furthermore,	 trivalent	
compound	 45,	 designed	 to	 bind	 in	 all	 three	 NNMT	 binding	
Scheme	 4.	 Synthesis	 of	 compound	 35.	 Reagents	 and	 conditions:	 a)	 1.	 Ethyl	
chloroformate,	N-methyl	morpholine,	THF,	-10°C	to	-5°C,	15	min	2.	NaBH4,	water,	5°C,	
3.5	h,	95%;	b)	MsCl,	DiPEA,	DCE,	0°C,	30	min,	66%;	c)	NaN3,	DMF,	rt,	16h,	72%;	d)	Pd/C,	
H2,	 EtOH,	 rt,	 1h,	89%;	e)	methyl-3-formylbenzoate,	Na(OAc)3BH,	DCE,	 rt,	 16h,	37%;	 f)	
TFA,	DCM,	rt,	1h;	g)	25%	NH3	(aq),	MeOH,	µW,	130°C,	3h.	
Scheme	5.	 Synthesis	 of	 compound	 41.	Reagents	 and	 conditions:	a)	 CBr4,	 PPh3,	 DCM,	
27%,	b)	SiO2:AcSK,	toluene,	rt,	1h,	91%;	c)	K2CO3,	MeOH,	rt,	2h,	93%;	d)	36,	K2CO3,	DMF,	
rt,	2h,	60%;	e)	TFA,	DCM,	rt,	1h;	f)	25%	NH3	(aq),	MeOH,	µW,	130°C,	3h.	
Scheme	 6.	 Synthesis	 of	 compound	 45.	 Reagents	 and	 conditions:	 a)	 O,N-dimethyl-
hydroxylamine.HCl,	BOP,	Et3N,	 DCM,	 rt,	 2h,	90%;	 b)	DiBAL-H	 in	hexanes	 (1M),	 THF,	 -
78°C,	87%,	c)	43,	Na(OAc)3BH,	DCE,	rt,	16h,	53%;	d)	25%	NH3	(aq),	MeOH,	µW,	130°C,	
3h;	e)	TFA,	DCM,	rt,	1h.	
Figure	 3.	 Structures	 of	 reference	 compounds	 AdoHcy,	 sinefungin,	 N’-methyl-
nicotinamide	 (MNA)	and	4-methyl-N’-methyl-nicotinamide	 (4MeMNA)	and	alternative	
NNMT	substrate	norharmane.
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pockets,	inhibits	NNMT	with	an	IC50	of	29.2	±	4.0	µM,	similar	to	
the	 inhibitory	 activity	 of	 reference	 inhibitors	 sinefungin	 and	
MNA.	
	 Modelling	 studies	 performed	 with	 compound	 45	 show	
interactions	 in	 the	 enzyme’s	 active	 site	 similar	 to	 those	
expected	 based	 upon	 the	 transition	 state	model	 (Fig.	 4).	 The	
docking	 analysis	 reveals	 that	 the	 spacing	 of	 the	 compound	
allows	 binding	 in	 all	 three	 binding	 pockets	 as	 hypothesized.	
Although	 the	NA	 pyridine	 ring	 is	 replaced	 by	 a	 benzene	 ring,	
the	 pi-pi-stacking	 with	 tyrosine	 residue	 Y204	 remains,	 which	
appears	 to	 be	 sufficient	 to	 compensate	 for	 the	 loss	 of	
interaction	 with	 the	 nitrogen	 in	 the	 pyridine	 ring	 of	 NA.	 All	
other	 interactions	 that	were	 found	 in	 the	 crystal	 structure	of	
NNMT	 in	 complex	 with	 nicotinamide	 and	 AdoHcy,	 shown	 in	
Figure	2,	are	visible	in	the	model	as	represented	in	Figure	4	as	
well.		
Conclusions	
We	 here	 describe	 the	 first	 systematic	 bisubstrate	 approach	
towards	the	discovery	of	inhibitors	of	NNMT.	While	a	number	
of	 partial	 bisubstrate	 analogues	 were	 explored,	 our	 results	
indicate	 that	 the	 best	mimic	 of	 the	 NNMT	 transition	 state	 is	
the	 trivalent	 compound	45.	 The	absence	of	 inhibitory	activity	
for	 the	 alkylated	 nicotinamides	 2a-i	 and	 adenosine-
nicotinamide	conjugates	9-11	are	somewhat	surprising.	While	
MNA	 shows	 an	 IC50	 of	 24.6	 µM,	N’-ethylnicotinamide	 has	 an	
IC50	 of	 >250	µM	as	 do	 analogues	 bearing	 larger	 alkyl	 groups.	
Furthermore,	 the	 simplified	 bisubstrate	 approach	 that	 we	
previously	 applied	 in	 generating	 potent	 inhibitors	 of	 the	
protein	arginine	methyltransferases17	was	not	successful	here	
as	compounds	9-11	displayed	essentially	no	NNMT	 inhibition.	
While	the	set	of	compounds	here	described	is	not	exhaustive,	
the	results	do	suggest	that	binding	in	at	least	the	nicotinamide	
and	 amino	 acid	 binding	 pockets	 is	 necessary	 for	 significant	
inhibition	 of	 the	 enzyme.	 An	 additional	 finding	 of	 interest	 is	
the	 inhibitory	 activity	 of	 norharmane,	 a	 known	 NNMT	
substrate	 with	 a	 low	 turnover	 rate.	 In	 this	 regard,	
incorporation	 of	 a	 norharmane	 mimic	 in	 future	 inhibitor	
designs	may	 prove	 useful.	 Future	 plans	 are	 aimed	 at	 further	
optimizing	compound	45	 in	an	attempt	to	enhance	 inhibition.	
To	 this	 end	 it	 is	 beneficial	 that	 the	 three	 main	 structural	
elements	found	in	45	can	be	modified	independently	and	with	
relative	 ease.	 Once	more	 potent	 NNMT	 inhibitors	 have	 been	
identified,	their	selectivity	and	activity	in	cell-based	assays	will	
be	assessed.	These	findings	will	be	reported	in	due	course.	
Experimental		
General	methods	
All	 reagents	 employed	 were	 of	 American	 Chemical	 Society	
(ACS)	grade	or	finer	and	were	used	without	further	purification	
unless	 otherwise	 stated.	 For	 compound	 characterization	 1H	
NMR	spectra	were	 recorded	at	400	MHz	with	 chemical	 shifts	
reported	 in	 parts	 per	 million	 (ppm)	 downfield	 relative	 to	
tetramethylsilane	 (TMS),	 H2O	 (δ	 4.79),	 methanol	 (δ	 3.31)	 or	
DMSO	 (δ	 2.50).	 1H	 NMR	 data	 are	 reported	 in	 the	 following	
order:	multiplicity	 (s,	 singlet;	 d,	 doublet;	 t,	 triplet;	 q,	 quartet	
and	m,	multiplet),	 coupling	 constant	 (J)	 in	 hertz	 (Hz)	 and	 the	
number	 of	 protons.	 Where	 appropriate,	 the	 multiplicity	 is	
preceded	by	br,	indicating	that	the	signal	was	broad.	13C	NMR	
spectra	 were	 recorded	 at	 101	 MHz	 with	 chemical	 shifts	
reported	 relative	 to	 CDCl3	 (δ	 77.16),	 methanol	 (δ	 49.00)	 or	
DMSO	 (δ	 39.52).	 The	 13C	 NMR	 spectra	 of	 the	 compounds	
recorded	in	D2O	could	not	be	referenced.	High-resolution	mass	
spectrometry	 (HRMS)	 analysis	 was	 performed	 using	 a	 Q-TOF	
instrument.	Compounds	3-517,	30-3323,	3620	and	42-4324	were	
synthesized	according	 to	previously	described	procedures.	All	
known	 compounds	 prepared	 had	 NMR	 spectra	 and	 mass	
spectra	 consistent	 with	 the	 assigned	 structures.	 Purity	 was	
confirmed	 to	 be	 ≥95%	 by	 analytical	 RP-HPLC	 using	 a	
Phenomenex	Kinetex	C18	column	(5	µm,	250	×	4.6	mm)	eluted	
with	 a	 water–	 acetonitrile	 gradient	 moving	 from	 0%	 to	 50%	
CH3CN	 (0.1%	 TFA)	 over	 30	 minutes	 at	 a	 flow	 rate	 of	 1.0	 ml	
min−1	with	UV	detection	at	214	nm	and	254	nm.	
	
General	procedure	alkylated	nicotinamides	
Nicotinamide	 (500	mg,	1.0	eq,	4.0	mmol)	was	dissolved	 in	10	
mL	dry	CH3CN,	followed	by	the	addition	of	R-I	or	R-Br	(2.2	eq,	9	
mmol).	The	tube	was	then	sealed	and	reacted	in	a	microwave	
for	 90	 minutes	 at	 140°C.	 If	 necessary,	 the	 product	 was	
precipitated	 with	 dry	 diethyl	 ether.	 The	 precipitated	 product	
was	filtered	off	and	washed	with	dry	diethyl	ether.	
1-Ethyl-3-carbamoyl-pyridinium	iodide	2a	
Synthesized	according	to	the	general	procedure	(92%	yield).	1H	
NMR	 (400	MHz,	D2O)	 δ	 9.38	 (s,	 1H),	 9.09	 (d,	 J	 =	 6.1	Hz,	 1H),	
8.92	(d,	J	=	8.2	Hz,	1H),	8.24	(t,	J	=	7.2	Hz,	1H),	4.78	(d,	J	=	7.4	
Hz,	 2H),	 1.71	 (t,	 J	 =	 7.4	 Hz,	 3H).	 13C	 NMR	 (101	MHz,	 D2O)	 δ	
165.9,	 146.2,	 144.0,	 143.8,	 133.9,	 128.4,	 58.0,	 15.6.	 HRMS	
(ESI):	calculated	for	C8H11N2O
+	151.0866,	found	151.0867.	
1-Propyl-3-carbamoyl-pyridinium	bromide	2b	
Synthesized	 according	 to	 the	 general	 procedure	 (697	 mg,	
71%).	1H	NMR	(400	MHz,	D2O)	δ	9.36	(s,	1H),	9.07	(d,	J	=	6.0	Hz,	
1H),	8.93	(d,	J	=	8.1	Hz,	1H),	8.24	(t,	J	=	7.2	Hz,	1H),	4.70	(t,	J	=	
7.3	 Hz,	 2H),	 2.18	 –	 2.04	 (m,	 2H),	 1.00	 (t,	 J	 =	 7.4	 Hz,	 3H).	 13C	
NMR	(101	MHz,	D2O)	δ	165.84,	146.47,	144.20,	143.82,	133.83,	
Figure	 4.	 Proposed	 hydrogen	 bond	 network	 after	 modelling	 and	 minimization	 of	
compound	45	(yellow)	in	the	NNMT	active	site	(aliphatic	hydrogens	omitted	for	clarity).
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128.33,	 63.86,	 24.12,	 9.63.	 HRMS	 (ESI):	 calculated	 for	
C9H13N2O
+	165.1022,	found	165.1020.	
1-Butyl-3-carbamoyl-pyridinium	bromide	2c	
Synthesized	 according	 to	 the	 general	 procedure	 (671	 mg,	
63%).	1H	NMR	(400	MHz,	D2O)	δ	9.35	(s,	1H),	9.07	(d,	J	=	6.1	Hz,	
1H),	8.93	(d,	J	=	8.2	Hz,	1H),	8.23	(t,	J	=	7.2	Hz,	1H),	4.73	(t,	J	=	
7.5	Hz,	2H),	2.12	–	2.00	(m,	2H),	1.49	–	1.34	(m,	2H),	0.98	(t,	J	=	
7.4	Hz,	3H).	13C	NMR	(101	MHz,	D2O)	δ	165.85,	146.43,	144.18,	
143.75,	133.84,	128.30,	62.30,	32.49,	18.68,	12.60.	HRMS	(ESI):	
calculated	for	C10H15N2O
+	179.1179,	found	179.1175.	
1-Allyl-3-carbamoyl-pyridinium	bromide	2d	
Synthesized	 according	 to	 the	 general	 procedure	 (800	 mg,	
80%).	1H	NMR	(400	MHz,	DMSO-d6)	δ	9.53	(s,	1H),	9.22	(d,	J	=	
5.5	Hz,	1H),	9.02	(d,	J	=	7.9	Hz,	1H),	8.65	(s,	1H),	8.31	(t,	J	=	6.8	
Hz,	1H),	8.18	(s,	1H),	6.34	–	6.13	(m,	1H),	5.58	–	5.43	(m,	2H),	
5.38	(d,	J	=	5.7	Hz,	2H).	13C	NMR	(101	MHz,	DMSO-d6)	δ	162.7,	
146.4,	 144.8,	 143.7,	 133.7,	 131.4,	 128.0,	 122.4,	 62.6.	 HRMS	
(ESI):	calculated	for	C9H11N2O
+	163.0866,	found	163.0863.	
1-Isopropyl-3-carbamoyl-pyridinium	iodide	2e	
Synthesized	 according	 to	 the	 general	 procedure	 (534	 mg,	
45%).	1H	NMR	(400	MHz,	D2O)	δ	9.37	(s,	1H),	9.14	(d,	J	=	5.9	Hz,	
1H),	8.91	(d,	J	=	7.8	Hz,	1H),	8.23	(t,	J	=	7.0	Hz,	1H),	5.19	–	5.07	
(m,	1H),	1.76	(s,	3H),	1.74	(s,	3H).	13C	NMR	(101	MHz,	DMSO-
d6)	δ	162.8,	144.6,	143.6,	142.9,	134.0,	128.1,	64.8,	22.3.	HRMS	
(ESI):	calculated	for	C9H13N2O
+	165.1022,	found	165.1016.	
1-Cyclopropylmethyl-3-carbamoyl-pyridinium	bromide	2f	
Synthesized	 according	 to	 the	 general	 procedure	 (335	 mg,	
63%).	1H	NMR	(400	MHz,	DMSO-d6)	δ	9.61	(s,	1H),	9.32	(d,	J	=	
5.0	Hz,	1H),	8.98	(d,	J	=	7.6	Hz,	1H),	8.63	(s,	1H),	8.28	(t,	J	=	6.5	
Hz,	1H),	8.16	 (s,	1H),	4.59	 (d,	 J	 =	7.0	Hz,	2H),	1.94	–	1.23	 (m,	
1H),	0.61	(s,	2H),	0.60	(s,	2H).	13C	NMR	(101	MHz,	DMSO-d6)	δ	
162.8,	146.1,	144.4,	143.6,	133.7,	127.9,	64.9,	12.0,	4.1.	HRMS	
(ESI):	calculated	for	C9H11N2O
+	177.1022,	found	177.1026.	
1-Cyclobutylmethyl-3-carbamoyl-pyridinium	bromide	2g	
Synthesized	 according	 to	 the	 general	 procedure	 (510	 mg,	
47%).	1H	NMR	(400	MHz,	D2O)	δ	9.28	(s,	1H),	9.01	(d,	J	=	6.1	Hz,	
1H),	8.92	(d,	J	=	8.0	Hz,	1H),	8.21	(t,	J	=	6.8	Hz,	1H),	4.75	(d,	J	=	
7.6	Hz,	2H),	3.01	(dt,	J	=	15.0,	7.7	Hz,	1H),	2.17	–	2.05	(m,	3H),	
2.01	–	1.86	 (m,	4H).	 13C	NMR	(101	MHz,	D2O)	δ	165.8,	146.2,	
143.7,	 141.9,	 133.8,	 128.3,	 66.4,	 35.8,	 17.4.	 HRMS	 (ESI):	
calculated	for	C11H15N2O
+	191.1179,	found	191.1181.	
1-Cyclohexylmethyl-3-carbamoyl-pyridinium	bromide	2h	
Synthesized	 according	 to	 the	 general	 procedure	 (342	 mg,	
29%).	1H	NMR	(400	MHz,	D2O)	δ	9.29	(s,	1H),	9.01	(d,	J	=	5.2	Hz,	
1H),	8.93	(d,	J	=	8.3	Hz,	1H),	8.23	(t,	J	=	7.3	Hz,	1H),	4.57	(d,	J	=	
7.3	Hz,	 2H),	 2.12	 –	 1.98	 (m,	 1H),	 1.83	 –	 1.54	 (m,	 4H),	 1.32	 –	
1.04	 (m,	6H).	 13C	NMR	 (101	MHz,	D2O)	δ	165.8,	146.6,	143.8,	
141.8,	 133.7,	 128.2,	 67.9,	 39.0,	 29.2,	 25.4,	 24.9.	 HRMS	 (ESI):	
calculated	for	C13H19N2O
+	219.1492,	found	219.1499.	
1-Benzyl-3-carbamoyl-pyridinium	bromide	2i	
Synthesized	 according	 to	 the	 general	 procedure	 (1063	 mg,	
89%).	1H	NMR	(400	MHz,	DMSO-d6)	δ	9.73	(s,	1H),	9.38	(d,	J	=	
6.0	Hz,	1H),	9.01	(d,	J	=	8.1	Hz,	1H),	8.66	(s,	1H),	8.30	(t,	J	=	7.1	
Hz,	1H),	8.20	(s,	1H),	7.64	–	7.58	(m,	2H),	7.47	–	7.38	(m,	3H),	
5.98	 (s,	 2H).	 	 13C	 NMR	 (101	MHz,	 DMSO-	 d6)	 δ	 162.7,	 146.4,	
144.8,	 143.9,	 134.0,	 134.0,	 129.4,	 129.2,	 129.1,	 128.3,	 63.4.	
HRMS	 (ESI):	 calculated	 for	 C13H13N2O
+	 213.1022,	 found	
213.1022.	
Methyl	 3-(((((3aR,4R,6R,6aR)-6-(6-amino-9H-purin-9-yl)-
2,2-dimethyltetrahydrofuro[3,4-d][1,3]-dioxol-4-yl)methyl)-
amino)methyl)benzoate	(6)	
Amine	3	(500	mg,	1.63	mmol,	1.05	eq)	was	dissolved	in	35	mL	
dry	DCE	and	methyl	3-formylbenzoate	(255	mg,	1.55	mmol,	1.0	
eq)	was	added	along	with	crushed	4Å	molsieves.	The	mixture	
was	 stirred	 for	 5	 hours	 at	 room	 temperature	 under	 N2	
atmosphere	 before	Na(OAc)3BH	 (461	mg,	 2.18	mmol,	 1.4	 eq)	
was	added	in	small	portions.	The	mixture	was	stirred	overnight	
at	 room	 temperature	 under	 N2	 atmosphere.	 Conversion	 was	
monitored	 by	 TLC	 (DCM:MeOH	 8:2).	 The	 solvent	 was	
evaporated,	 redissolved	 in	 150	 mL	 DCE	 and	 filtered.	 The	
organic	 layer	 was	 washed	 with	 saturated	 NaHCO3	 and	 the	
aqueous	 layer	 extracted	 with	 DCM.	 The	 organic	 layer	 was	
dried	 with	 Na2SO4,	 filtered	 and	 concentrated	 yielding	 6	 (537	
mg,	 75%).	 1H	 NMR	 (400	MHz,	 CDCl3):	 δ	 8.12	 (s,	 1H),	 7.96	 (s,	
1H),	 7.92	 (d,	 J	=	7.7	Hz,	 1H),	 7.87	 (s,	 1H),	 7.49	 (d,	 J	=	7.5	Hz,	
1H),	7.37	(t,	J	=	7.6	Hz,	1H),	6.03	–	5.89	(m,	3H),	5.49	(dd,	J	=	
6.3,	3.3	Hz,	1H),	5.08	(dd,	J	=	6.3,	3.0	Hz,	1H),	4.44	–	4.36	(m,	
1H),	3.90	(s,	3H),	3.88	–	3.78	(m,	2H),	3.00	–	2.82	(m,	2H),	2.35	
(s,	1H),	1.62	(s,	3H),	1.39	(s,	3H).	13C	NMR	(101	MHz,	CDCl3):	δ	
167.2,	 155.8,	 153.2,	 149.5,	 140.6,	 140.1,	 132.7,	 130.4,	 129.3,	
128.6,	 128.4,	 120.6,	 114.6,	 91.2,	 85.6,	 83.4,	 82.4,	 53.5,	 52.2,	
50.8,	27.5,	25.5.	
3-(((((2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-di-
hydroxytetrahydrofuran-2-yl)methyl)amino)-methyl)	
benzamide	(9)	
Compound	 6	 (128	 mg,	 0.27	 mmol)	 was	 dissolved	 in	 1	 mL	
MeOH	and	1	mL	25%	NH3	(aq)	and	crimp	sealed.	The	mixture	
was	 reacted	 for	 4	 hours	 at	 130°C	 in	 the	 microwave.	 The	
mixture	 was	 concentrated	 and	 redissolved	 in	 7	 mL	 TFA:H2O	
(5:2).	After	45	minutes	at	room	temperature,	the	mixture	was	
concentrated	and	purified	by	preparative	HPLC.	1H	NMR	(D2O):	
δ	8.39	(s,	1H),	8.17	(s,	1H),	7.83	(d,	J	=	7.9	Hz,	1H),	7.78	(s,	1H),	
7.65	(d,	J	=	7.8	Hz,	1H),	7.55	(t,	J	=	7.7	Hz,	1H),	6.15	(d,	J	=	4.2	
Hz,	1H),	4.90	–	4.77	(m,	1H+	H2O),	4.54	(t,	J	=	5.3	Hz,	1H),	4.49	
–	4.32	(m,	4H),	3.64	–	3.37	(m,	3H).	13C	NMR	(101	MHz,	D2O)	δ	
171.5,	 148.1,	 147.7,	 133.7,	 133.3,	 130.8,	 129.5,	 128.9,	 128.3,	
119.2,	90.1,	79.8,	73.3,	71.5,	50.4,	47.9.	HRMS:	calculated	 for	
C18H21N7O4	[M+H]
+	400.1728,	found	400.1758.	
Methyl	 3-(((((3aR,4R,6R,6aR)-6-(6-amino-9H-purin-9-yl)-
2,2-dimethyltetrahydrofuro[3,4-d][1,3]-dioxol-4-yl)methyl)	
thio)methyl)benzoate	(7)	
Thioacetate	4	(546	mg,	1.5	mmol,	1.0	eq)	was	dissolved	 in	30	
mL	 dry	 deoxygenated	 methanol	 and	 methyl-3-bromomethyl-
benzoate	(514	mg,	2.2	mmol,	1.5	eq)	was	added.	The	mixture	
was	 cooled	 to	 -20°C	 and	 freshly	 prepared	 sodium	methoxide	
(from	82	mg	Na(s)	in	3	mL	MeOH)	was	added.	The	mixture	was	
stirred	overnight	at	 room	temperature	under	N2	atmosphere.	
The	 solvent	 was	 evaporated,	 redissolved	 in	 chloroform	 and	
washed	with	water.	The	organic	layer	was	dried,	concentrated	
and	purified	by	column	chromatography	(2.5%	MeOH	in	DCM)	
yielding	7	(450	mg,	64%)	1H	NMR	(400	MHz,	CDCl3):	δ	8.27	(s,	
1H),	7.94	–	7.84	(m,	3H),	7.39	(d,	J	=	7.6	Hz,	1H),	7.31	(t,	J	=	7.6	
Hz,	1H),	6.07	–	6.00	(m,	3H),	5.44	(dd,	J	=	6.4,	1.9	Hz,	1H),	4.99	
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(dd,	J	=	6.3,	3.4	Hz,	1H),	4.33	(td,	J	=	6.6,	3.4	Hz,	1H),	3.89	(s,	
3H),	3.72	(s,	2H),	2.71	(ddd,	J	=	43.7,	13.7,	6.7	Hz,	2H),	1.59	(s,	
3H),	1.37	 (s,	3H).	 	 13C	NMR	 (101	MHz,	CDCl3):	δ	166.9,	155.8,	
153.2,	 149.3,	 140.0,	 138.4,	 133.4,	 130.6,	 130.0,	 128.7,	 128.5,	
120.4,	114.6,	90.8,	86.8,	84.1,	83.9,	52.3,	36.3,	33.5,	27.2,	25.5.	
3-(((((2S,3S,4R,5R)-5-(6-Amino-9H-purin-9-yl)-3,4-di-
hydroxytetrahydrofuran-2-yl)methyl)thio)methyl)benzamide	
(10)	
Compound	 7	 (100	 mg,	 0.21	 mmol)	 was	 dissolved	 in	 1	 mL	
MeOH	and	1	mL	25%	NH3	(aq)	and	crimp	sealed.	The	mixture	
was	 reacted	 for	 4	 hours	 at	 130°C	 in	 the	 microwave.	 The	
mixture	 was	 concentrated	 and	 redissolved	 in	 7	 mL	 TFA:H2O	
(5:2).	After	45	minutes	at	room	temperature,	the	mixture	was	
concentrated	and	purified	by	preparative	HPLC.	 1H	NMR	 (400	
MHz,	CD3OD):	δ	8.43	(s,	1H),	8.33	(s,	1H),	7.71	(s,	1H),	7.68	(d,	J	
=	7.7	Hz,	1H),	7.47	(d,	 J	=	7.6	Hz,	1H),	7.40	(t,	 J	=	7.6	Hz,	1H),	
6.05	(d,	J	=	4.8	Hz,	1H),	4.78	(t,	J	=	5.1	Hz,	1H),	4.34	(t,	J	=	5.1	
Hz,	1H),	4.24	 (dt,	 J	=	6.5,	4.8	Hz,	1H),	3.82	 (d,	 J	=	2.2	Hz,	2H),	
2.92	 (dd,	 J	=	14.2,	4.8	Hz,	1H),	2.82	 (dd,	 J	=	14.2,	6.7	Hz,	1H).	
13C	 NMR	 (101	 MHz,	 CD3OD)	 δ	 172.7,	 149.5,	 140.1,	 134.2,	
133.8,	129.9,	128.8,	127.1,	120.1,	89.9,	85.3,	74.6,	73.6,	67.7,	
36.8,	34.0.	HRMS:	calculated	for	C18H21N6O4S	[M+H]
+	417.1340,	
found	417.1366.	
Methyl	 3-((((3aR,4R,6R,6aR)-6-(6-(N-benzoylbenzamido)-
9H-purin-9-yl)-2,2-dimethyltetrahydrofuro-[3,4-d][1,3]dioxol-
4-yl)methoxy)methyl)benzoate	(8)	
The	 protected	 adenosine	 5	 (1.0	 g,	 1.94	 mmol,	 1.0	 eq)	 was	
added	 to	 a	 suspension	 of	 sodium	 hydride	 as	 dispersion	 in	
mineral	oil	(103	mg,	2.14	mmol,	1.1	eq)	dissolved	in	15	mL	dry	
DMF.	 After	 30	 minutes	 a	 solution	 of	 methyl-3-
bromomethylbenzoate	(580	mg,	2.52	mmol,	1.3	eq)	in	DMF	(2	
mL)	was	added	slowly	and	the	mixture	was	stirred	overnight	at	
room	temperature.	The	reaction	was	quenched	with	saturated	
NH4Cl	 and	 the	 mixture	 was	 concentrated.	 The	 residue	 was	
redissolved	 in	 EtoAc	 and	 washed	 with	 saturated	 NH4Cl.	 The	
aqueous	 phase	 was	 extracted	 with	 EtoAc	 and	 the	 combined	
organic	 layers	 were	 dried	 over	 sodium	 sulfate,	 concentrated	
and	purified	by	column	chromatography	(2.5%	MeOH	in	DCM)	
yielding	8	(450	mg,	64%).	1H	NMR	(400	MHz,	CDCl3):	δ
	8.49	(s,	
1H),	8.09	(s,	1H),	7.96	(s,	1H),	7.92	(d,	J	=	7.5	Hz,	2H),	7.84	(d,	J	
=	7.7	Hz,	1H),	7.72	(d,	 J	=	7.8	Hz,	1H),	7.52	(t,	 J	=	7.4	Hz,	1H),	
7.45	(d,	J	=	7.5	Hz,	2H),	7.36	(t,	J	=	7.8	Hz,	2H),	7.31	(t,	J	=	7.7	
Hz,	1H),	7.28	–	7.21	(m,	1H),	7.14	(t,	J	=	7.6	Hz,	2H),	6.06	(d,	J	=	
2.3	Hz,	1H),	5.62	 (d,	 J	 =	2.5	Hz,	2H),	5.45	 (dd,	 J	 =	6.4,	2.3	Hz,	
1H),	5.10	(dd,	J	=	6.3,	3.3	Hz,	1H),	4.60	–	4.49	(m,	2H),	4.43	(dd,	
J	=	11.5,	5.3	Hz,	1H),	3.85	(s,	3H),	1.61	(s,	3H),	1.38	(s,	3H).		13C	
NMR	 (101	 MHz,	 CDCl3):	 δ	 172.1,	 167.0,	 166.1,	 154.3,	 152.2,	
152.0,	 142.7,	 138.0,	 135.9,	 133.4,	 132.6,	 131.1,	 130.3,	 129.7,	
129.6,	 129.4,	 129.3,	 128.9,	 128.7,	 128.6,	 128.6,	 128.5,	 128.0,	
127.0,	115.1,	91.1,	84.7,	83.9,	81.4,	64.0,	52.1,	51.2,	27.3,	25.5.	
3-(((((2S,3S,4R,5R)-5-(6-Amino-9H-purin-9-yl)-3,4-di-
hydroxytetrahydrofuran-2-yl)methoxy)methyl)benzamide	
(11)	
Compound	 8	 (100	 mg,	 0.21	 mmol)	 was	 dissolved	 in	 1	 mL	
MeOH	and	1	mL	25%	NH3	(aq)	and	crimp	sealed.	The	mixture	
was	 reacted	 for	 4	 hours	 at	 130°C	 in	 the	 microwave.	 The	
mixture	 was	 concentrated	 and	 redissolved	 in	 7	 mL	 TFA:H2O	
(5:2).	After	45	minutes	at	room	temperature,	the	mixture	was	
concentrated	and	purified	by	preparative	HPLC.	 1H	NMR	 (400	
MHz,	D2O):	δ	8.47	(s,	1H),	8.36	(s,	1H),	7.79	(s,	1H),	7.74	(d,	J	=	
7.5	Hz,	1H),	7.61	(d,	J	=	7.5	Hz,	1H),	7.50	(t,	J	=	7.7	Hz,	1H),	6.13	
(d,	J	=	5.2	Hz,	1H),	5.00	–	4.83	(m,	2H),	4.76	(t,	J	=	5.3	Hz,	1H),	
4.44	(t,	J	=	5.1	Hz,	1H),	4.29	(d,	J	=	30.9	Hz,	1H),	3.97	–	3.79	(m,	
2H).	 13C	 NMR	 (101	 MHz,	 D2O)	 δ	
13C	 NMR	 (101	 MHz,	 d2o)	 δ	
172.4,	 133.1,	 131.1,	 129.2,	 126.8,	 126.1,	 117.7,	 114.8,	 88.5,	
85.6,	 74.1,	 70.2,	 61.1.	 HRMS:	 calculated	 for	 C18H21N6O5	
[M+Na]+	423.1387,	found	423.1411.	
5-(3-Carbamoylphenyl)pent-4-ynoic	acid	(12)	
To	a	 suspension	of	 4-pentynoic	 acid	 (122	mg,	 1.24	mmol),	 3-
iodo-N-tritylbenzamide	 (490	 mg,	 1.0	 mmol)	 and	 TEA	 (5	 ml),	
Pd(PPh3)2Cl2	 (14	 mg,	 0.02	 mmol)	 was	 added	 and	 stirred	 at	
room	temperature	for	5	minutes	under	N2	environment.	After	
addition	 of	 THF	 (2	 ml)	 and	 Cu(I)I	 (8	 mg,	 0.04	 mmol),	 the	
mixture	 was	 heated	 to	 50°C	 for	 4	 hours.	 The	 solvent	 was	
evaporated	 in	 vacuo,	 and	 the	 crude	 product	 was	 purified	 by	
column	chromatography	(SiO2:	DCM	-	5%	MeOH)	affording	the	
trityl-protected	 product	 (89	 mg,	 20%)	 as	 an	 orange	 powder.	
The	 intermediate	was	dissolved	 in	DCM	(2	mL)	and	a	mixture	
of	 TFA/TIPS/H2O	 (95:2.5:2.5,	 5	 mL)	 was	 added.	 After	 full	
deprotection	 as	 determined	 via	 TLC	 (DCM	 /	 5%	MeOH),	 the	
mixture	was	concentrated	and	purified	by	preparative	HPLC	to	
yield	compound	12	as	a	white	powder	(21	mg,	50%).	1H	NMR	
(400	MHz,	CD3OD)	δ	7.88	(s,	1H),	7.77	(d,	J	=	7.8	Hz,	1H),	7.53	
(d,	 J	=	7.7	Hz,	1H),	7.41	 (t,	 J	=	7.8	Hz,	1H),	2.72	 (t,	 J	=	7.2	Hz,	
2H),	 2.51	 (t,	 J	 =	 7.3	 Hz,	 2H).	 13C	 NMR	 (101	 MHz,	 CD3OD)	 δ	
176.9,	 171.5,	 135.6,	 135.3,	 131.7,	 129.6,	 127.9,	 125.5,	 90.3,	
81.3,	 35.5,	 16.4.	 HRMS:	 calculated	 for	 C12H11NO3	 [M+H]
+:	
218.0812,	found	218.0804.	
5-(3-Carbamoylphenyl)pent-4-ynoic	amide	(13)	
Following	the	procedure	described	for	compound	12,	coupling	
4-pentynoic	 amide	 (117	mg,	1.2	mmol)	 and	3-iodobenzamide	
(247	mg,	1.0	mmol)	afforded	compound	13	(169	mg,	78%)	as	a	
white	 powder.	 1H	 NMR	 (400	 MHz,	 DMSO-d6)	 δ	 7.99	 (s,	 1H),	
7.83	 (s,	 1H),	 7.78	 (d,	 J	 =	 7.7	Hz,	 1H),	 7.46	 (d,	 J	 =	 7.5	Hz,	 1H),	
7.41	–	7.31	(m,	2H),	6.85	(s,	1H),	2.59	(t,	J	=	7.3	Hz,	2H),	2.32	(t,	
J	=	7.3	Hz,	2H).	13C	NMR	(101	MHz,	DMSO-d6)	δ	172.76,	167.48,	
134.99,	 134.18,	 130.59,	 129.03,	 127.47,	 123.52,	 91.10,	 80.33,	
34.47,	 15.41.	 HRMS:	 calculated	 for	 C12H12N2O2	 [M+H]
+:	
217.0972,	found	217.0991.	
6-(3-Carbamoylphenyl)hex-5-ynoic	acid	(14)	
Following	the	procedure	described	for	compound	12,	coupling	
of	 5-hexynoic	 acid	 (137	 mg,	 1.22	 mmol)	 and	 3-iodo-N-
tritylbenzamide	 (490	 mg,	 1.0	 mmol)	 afforded	 the	 trityl-
protected	 intermediate	 (232	 mg,	 49	 %)	 as	 a	 peach	 colored	
powder.	 The	 deprotection	 and	 purification	 procedure	 on	 0.2	
mmol	 scale	 as	 described	 for	 compound	 12	 afforded	 final	
compound	14	(21	mg,	42%).	1H	NMR	(400	MHz,	CD3OD)	δ	7.86	
(s,	1H),	7.76	(d,	J	=	7.8,	1.7	Hz,	1H),	7.51	(d,	J	=	7.7,	1.6	Hz,	1H),	
7.38	(t,	J	=	1.8	Hz,	1H),	2.51	–	2.43	(m,	4H),	1.92	–	1.82	(m,	2H).	
13C	NMR	(101	MHz,	CD3OD)	δ	175.46,	170.13,	134.18,	133.79,	
130.20,	 128.17,	 126.42,	 124.21,	 89.49,	 79.97,	 32.33,	 23.68,	
17.98.	 HRMS:	 calculated	 for	 C13H13NO3	 [M+H]
+:	 232.0968,	
found	232.0974.	
6-(3-Carbamoylphenyl)hex-5-ynoic	amide	(15)	
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Following	the	procedure	described	for	compound	12,	coupling	
5-hexynoic	 amide	 (133	 mg,	 1.2	 mmol)	 and	 3-iodobenzamide	
(247	mg,	1.0	mmol)	afforded	compound	15	(144	mg,	63%)	as	a	
white	 powder.	 1H	 NMR	 (400	 MHz,	 DMSO-d6)	 δ	 7.99	 (s,	 1H),	
7.85	(s,	1H),	7.78	(d,	J	=	7.8	Hz,1H),	7.50	(d,	J	=	7.7	Hz,	1H),	7.41	
–	7.36	(m,	2H),	7.28	(s,	1H),	6.73	(s,	1H),	2.41	(t,	J	=	7.0	Hz,	2H),	
2.19	(t,	J	=	7.4	Hz,	2H),	1.76	–	1.68	(m,	2H).	13C	NMR	(101	MHz,	
DMSO-d6)	 δ	 174.03,	 167.49,	 134.97,	 134.22,	 130.59,	 129.02,	
127.46,	 123.61,	 91.24,	 80.74,	 34.33,	 24.57,	 18.72.	 HRMS:	
calculated	for	C13H13N2O2	[M+H]
+:	231.1128,	found	231.1131.	
7-(3-Carbamoylphenyl)hept-6-ynoic	acid	(16)	
Following	the	procedure	described	for	compound	12,	coupling	
6-heptynoic	 acid	 (302.7	 mg,	 2.4	 mmol)	 and	 3-iodo-N-
tritylbenzamide	 (980	 mg,	 2.0	 mmol)	 afforded	 the	 trityl-
protected	 intermediate	 (712	 mg,	 72	 %)	 as	 a	 yellow	 oil.	 The	
deprotection	and	purification	procedure	on	0.2	mmol	scale	as	
described	 for	 compound	 12	 afforded	 final	 compound	 16	 (15	
mg,	27%	isolated	yield).	1H	NMR	(400	MHz,	CD3OD)	δ	7.84	(s,	
1H),	7.75	(d,	J	=	7.8	Hz,	1H),	7.51	(d,	J	=	7.6	Hz,	1H),	7.38	(t,	J	=	
7.8	Hz,	1H),	2.44	(t,	J	=	6.9	Hz,	2H),	2.34	(t,	J	=	7.2	Hz,	2H),	1.80	
–	1.72	(m,	2H),	1.66	–	1.58	(m,	2H).	13C	NMR	(101	MHz,	CD3OD)	
δ	177.5,	171.7,	135.6,	135.1,	131.6,	129.6,	127.7,	125.7,	91.6,	
81.0,	 34.4,	 29.1,	 25.3,	 19.6.	 HRMS:	 calculated	 for	 C14H15NO3	
[M+Na]+:	268.0944,	found	268.0941.	
7-(3-Carbamoylphenyl)hept-6-ynoic	amide	(17)	
Following	the	procedure	described	for	compound	12,	coupling	
5-hexynoic	 amide	 (150	 mg,	 1.2	 mmol)	 and	 3-iodo-N-
tritylbenzamide	 (247	 mg,	 0.5	 mmol)	 afforded	 the	 trityl-
protected	 intermediate	 (218	 mg,	 89	 %)	 as	 a	 yellow	 powder.	
The	 deprotection	 and	 purification	 procedure	 on	 0.2	 mmol	
scale	as	described	 for	compound	12	afforded	 final	compound	
17	 (22	mg,	 44%	 isolated	 yield).	 1H	NMR	 (400	MHz,	 CD3OD)	 δ	
7.88	 (s,	 1H),	 7.78	 (d,	 J	 =	 7.8	Hz,	 1H),	 7.53	 (d,	 J	 =	 7.7	Hz,	 1H),	
7.40	(t,	J	=	7.8	Hz,	1H),	2.47	(t,	J	=	6.9	Hz,	3H),	2.27	(t,	J	=	7.4	
Hz,	2H),	1.85	–	1.76	(m,	3H),	1.69	–	1.61	(m,	3H).	13C	NMR	(101	
MHz,	CD3OD)	δ	178.9,	171.6,	135.6,	135.2,	131.6,	129.6,	127.8,	
125.8,	91.6,	81.1,	36.0,	29.3,	26.1,	19.7.	HRMS:	calculated	 for	
C14H16N2O2	[M+H]
+:	245.1258,	found	245.1185.	
5-(3-Carbamoylphenyl)pentanoic	acid	(18)	
To	a	solution	of	the	trityl-protected	intermediate	of	compound	
12	(90	mg,	0.19	mmol)	 in	MeOH	(5	mL),	a	suspension	of	Pd/C	
(10	%,	20	mg,	excess)	in	MeOH	(5	mL)	was	added.	The	mixture	
was	 hydrogenated	 using	 an	 H2-balloon	 for	 2	 hours.	 The	
catalyst	was	removed	by	 filtration	over	celite	and	the	solvent	
was	evaporated	in	vacuo,	affording	the	trityl-protected	alkane	
(56	 mg,	 62	 %)	 as	 a	 white	 powder.	 The	 deprotection	 and	
purification	procedure	as	described	for	compound	12	afforded	
final	 compound	 18	 (9	 mg,	 33%	 isolated	 yield).	 1H	 NMR	 (400	
MHz,	CD3OD)	δ	7.69	(s,	1H),	7.66	(d,	J	=	6.7	Hz,	1H),	7.38	–	7.31	
(m,	2H),	2.67	(d,	J	=	7.0	Hz,	2H),	2.30	(d,	J	=	7.1	Hz,	2H),	1.70	–	
1.59	 (m,	 4H).	 13C	 NMR	 (101	 MHz,	 CD3OD)	 δ	 177.5,	 172.6,	
144.0,	134.9,	133.1,	129.5,	128.6,	126.2,	36.4,	34.7,	31.9,	25.6.	
HRMS:	 calculated	 for	 C12H15NO3	 [M+H]
+:	 222.1125,	 found	
222.1137.	
5-(3-Carbamoylphenyl)pentanoic	amide	(19)	
Compound	13	(100	mg,	0.46	mmol)	was	reduced	following	the	
procedure	 described	 for	 compound	 18	 affording	 final	
compound	19	 (69	mg,	67%)	as	a	white	powder.	 1H	NMR	(400	
MHz,	CD3OD)	δ	7.71	(s,	1H),	7.68	(d,	J	=	6.8	Hz,	1H),	7.40	–	7.33	
(m,	2H),	2.71	(t,	J	=	7.1	Hz,	2H),	2.24	(t,	J	=	7.2	Hz,	2H),	1.72	–	
1.62	 (m,	 4H).	 13C	 NMR	 (101	 MHz,	 CD3OD)	 δ	 179.1,	 172.6,	
144.1,	135.0,	133.1,	129.5,	128.6,	126.2,	36.4,	36.3,	32.0,	26.4.	
HRMS:	 calculated	 for	 C12H16N2O2	 [M+H]
+:	 221.1285,	 found	
221.1294.	
6-(3-Carbamoylphenyl)hexanoic	acid	(20)	
Compound	14	(100	mg,	0.21	mmol)	was	reduced	following	the	
procedure	 described	 for	 compound	 18	 affording	 the	 trityl-
protected	 alkane	 (88	 mg,	 88	 %)	 as	 a	 white	 powder.	 The	
deprotection	 and	 purification	 procedure	 as	 described	 for	
compound	 12	 afforded	 final	 compound	 20	 (15	 mg,	 29%	
isolated	yield).	1H	NMR	(400	MHz,	CD3OD)	δ	7.71	(s,	1H),	7.67	
(d,	J	=	6.8	Hz,	1H),	7.40	–	7.33	(m,	2H),	2.69	(t,	J	=	7.6	Hz,	2H),	
2.28	(t,	J	=	7.4	Hz,	2H),	1.72	–	1.61	(m,	4H),	1.43	–	1.34	(m,	2H).	
13C	 NMR	 (101	 MHz,	 CD3OD)	 δ	 177.6,	 172.7,	 144.3,	 134.9,	
133.1,	 129.5,	 128.6,	 126.1,	 49.6,	 49.4,	 49.2,	 49.0,	 49.0,	 48.8,	
48.6,	 48.4,	 36.5,	 34.8,	 32.2,	 29.7,	 25.9.	 HRMS:	 calculated	 for	
C13H17NO3	[M+H]
+:	236.1281,	found	236.1290.	
6-(3-Carbamoylphenyl)hexanoic	amide	(21)	
Compound	15	 (96	mg,	0.42	mmol)	was	reduced	following	the	
procedure	 described	 for	 compound	 18	 affording	 final	
compound	21	 (21	mg,	22%)	as	a	white	powder.	 1H	NMR	(400	
MHz,	CD3OD)	δ	7.71	(s,	1H),	7.67	(d,	J	=	6.8	Hz,	1H),	7.39	–	7.33	
(m,	2H),	2.69	(d,	J	=	7.6	Hz,	2H),	2.20	(d,	J	=	7.4	Hz,	2H),	1.73	–	
1.61	(m,	4H),	1.43	–	1.33	(m,	2H).	13C	NMR	(101	MHz,	CD3OD)	δ	
179.2,	 172.6,	 144.3,	 134.9,	 133.1,	 129.5,	 128.7,	 126.1,	 36.5,	
36.4,	32.2,	29.7,	26.6.	HRMS:	calculated	for	C13H18N2O2	[M+H]
+:	
235.1441,	found	235.1450.	
7-(3-Carbamoylphenyl)heptanoic	acid	(22)	
Compound	16	(100	mg,	0.21	mmol)	was	reduced	following	the	
procedure	 described	 for	 compound	 18	 affording	 the	 trityl-
protected	 alkane	 (80	 mg,	 79	 %)	 as	 a	 white	 powder.	 The	
deprotection	 and	 purification	 procedure	 as	 described	 for	
compound	 12	 (0.1	 mmol	 scale)	 afforded	 final	 compound	 22	
(7.4	mg,	30%	isolated	yield).	1H	NMR	(400	MHz,	CD3OD)	δ	7.71	
(s,	1H),	7.68	(d,	J	=	6.5	Hz,	1H),	7.41	–	7.34	(m,	2H),	2.69	(t,	J	=	
7.5	Hz,	2H),	2.28	(t,	J	=	7.3	Hz,	2H),	1.71	–	1.56	(m,	4H),	1.42	–	
1.35	 (m,	 4H).	 13C	 NMR	 (101	 MHz,	 CD3OD)	 δ	 172.7,	 144.5,	
134.9,	133.1,	129.5,	128.6,	126.1,	36.6,	35.0,	32.4,	30.0,	29.9,	
26.0.	HRMS:	calculated	for	C14H19NO3	[M+H]
+:	250.1438,	found	
250.1439.	
7-(3-Carbamoylphenyl)heptanoic	amide	(23)	
Compound	17	 (90	mg,	0.19	mmol)	was	reduced	following	the	
procedure	 described	 for	 compound	 18	 affording	 the	 trityl-
protected	 alkane	 (69	 mg,	 76%)	 as	 a	 white	 powder.	 The	
deprotection	 and	 purification	 procedure	 as	 described	 for	
compound	 12	 afforded	 final	 compound	 23	 (12	 mg,	 36%	
isolated	 yield).	 1H	 NMR	 (400	 MHz,	 DMSO-d6)	 δ	 7.92	 (s,	 1H),	
7.71	–	7.64	(m,	2H),	7.37	–	7.26	(m,	3H),	7.21	(s,	1H),	6.66	(s,	
1H),	2.60	(tj,	J	=	7.5	Hz,	2H),	2.01	(t,	J	=	7.4	Hz,	2H),	1.63	–	1.52	
(m,	2H),	1.51	–	1.42	(m,	2H),	1.34	–	1.20	(m,	4H).	13C	NMR	(101	
MHz,	 DMSO-d6)	 δ	 174.3,	 168.0,	 142.3,	 134.2,	 131.1,	 128.1,	
127.4,	 124.8,	 35.1,	 35.0,	 30.8,	 28.5,	 28.4,	 25.0.	 HRMS:	
calculated	for	C14H20N2O2	[M+H]
+:	249.1598,	found	249.1603.	
(Z)-6-(3-Carbamoylphenyl)hex-5-enoic	acid	(24)	
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Alkyne	20	 (70	mg,	 0.30	mmol)	 was	 selectively	 reduced	 using	
Lindlar	catalyst	(15	mg,	20%	w/w)	in	MeOH	(3.5	mL)	under	H2	
atmosphere	at	room	temperature.	After	3	hours,	the	reaction	
was	 complete	 as	 seen	 by	 NMR.	 The	 catalyst	 was	 filtered	 off	
over	 celite,	 the	 solvent	 evaporated	 and	 the	 crude	 product	
purified	 by	 preparative	 HPLC	 affording	 (Z)-alkene	 24	 (60	mg,	
0.26	mmol,	85%).	1H	NMR	(400	MHz,	DMSO-d6)	δ	7.96	(s,	1H),	
7.77	–	7.70	(m,	2H),	7.46	–	7.40	(m,	2H),	7.35	(s,	1H),	6.47	(d,	J	
=	11.7	Hz,	1H),	5.71	(dt,	J	=	11.7,	7.2	Hz,	1H),	2.31	(q,	J	=	6.8	Hz,	
2H),	2.24	 (t,	 J	=	7.4	Hz,	2H),	1.65	 (p,	 J	=	7.5	Hz,	2H).	 13C	NMR	
(101	 MHz,	 DMSO-d6)	 δ	 167.8,	 163.1,	 137.0,	 134.4,	 132.7,	
131.1,	 128.6,	 128.2,	 127.6,	 125.7,	 33.1,	 27.5,	 24.6.	 HRMS:	
calculated	for	C13H15NO3	[M+Na]
+:	256.0944,	found	256.0966.	
(E)-6-(3-Carbamoylphenyl)hex-5-enoic	acid	(25)	
Alkyne	20	(50	mg,	0.22	mmol)	was	selectively	reduced	using	a	
Cp*RuCl(cod)	catalyst	(4.1	mg,	5	mol-%)	 in	DCM	(3	mL)	under	
H2	atmosphere	at	room	temperature.	After	overnight	stirring,	
NMR	shows	60%	conversion	with	>95%	E-alkene.	The	catalyst	
was	 filtered	 off	 over	 celite,	 the	 solvent	 evaporated	 and	 the	
crude	 product	 purified	 by	 preparative	 HPLC	 affording	 (E)-
alkene	25.	1H	NMR	(400	MHz,	DMSO-d6)	δ	7.97	(s,	1H),	7.90	(s,	
1H),	7.71	(d,	J	=	7.0	Hz,	1H),	7.52	(d,	J	=	7.0	Hz,	1H),	7.44	–	7.26	
(m,	2H),	6.51	–	6.29	(m,	2H),	2.38	–	2.10	(m,	4H),	1.77	–	1.60	
(m,	2H).	 13C	NMR	(101	MHz,	DMSO-d6)	δ	174.3,	167.8,	137.3,	
134.5,	 131.0,	 129.5,	 128.7,	 128.5,	 126.0,	 124.7,	 33.1,	 31.8,	
24.1.	HRMS:	calculated	for	C13H15NO3	[M+H]
+:	234.1125,	found	
234.1143.	
(S)-2-((Tert-butoxycarbonyl)amino)-6-(3-
carbamoylphenyl)	hex-5-ynoic	acid	(26)		
Following	the	procedure	described	for	compound	12,	coupling	
Boc-L-homopropargylglycine	 (114	 mg,	 0.5	 mmol)	 and	 3-
iodobenzamide	 (130	 mg,	 0.5	 mmol)	 afforded	 compound	 26	
(140	mg,	81%)	as	a	white	powder.	1H	NMR	(400	MHz,	DMSO-
d6)	δ	8.02	(s,	1H),	7.88	(s,	1H),	7.82	(d,	J	=	7.8	Hz,	1H),	7.52	(d,	J	
=	7.6	Hz,	1H),	7.47	–	7.37	(m,	2H),	7.14	(d,	J	=	7.9	Hz,	1H),	4.11	
–	3.98	(m,	1H),	2.57	–	2.43	(m,	2H),	2.02	–	1.77	(m,	2H),	1.38	(s,	
9H).	 13C	 NMR	 (101	 MHz,	 DMSO-d6)	 δ	 173.8,	 167.1,	 155.6,	
134.6,	133.8,	130.2,	128.6,	127.1,	123.0,	90.1,	80.5,	78.1,	52.7,	
29.9,	28.2,	15.8.	
(S)-2-Amino-6-(3-carbamoylphenyl)hex-5-ynoic	acid	(27)	
Compound	26	(70	mg,	0.2	mmol)	was	deprotected	in	TFA/DCM	
(1:1,	4	mL)	for	2	hours	at	room	temperature.	The	mixture	was	
concentrated	 and	 the	 product	 purified	 by	 preparative	 HPLC	
affording	compound	27	as	a	white	powder.	1H	NMR	(400	MHz,	
DMSO-d6)	δ	8.34	(br	s,	2H),	8.02	(s,	1H),	7.90	(s,	1H),	7.84	(d,	J	
=	7.8	Hz,	1H),	7.55	(d,	J	=	7.7	Hz,	1H),	7.49	–	7.40	(m,	2H),	4.03	
(t,	J	=	6.0	Hz,	1H),	2.74	–	2.53	(m,	2H),	2.19	–	1.97	(m,	2H).	13C	
NMR	(101	MHz,	DMSO-d6)	δ	170.6,	167.0,	134.6,	133.8,	130.3,	
128.6,	 127.2,	 122.8,	 89.0,	 81.0,	 51.2,	 29.2,	 15.1.	 HRMS:	
calculated	for	C13H14N2O3	[M+H]
+:	247.1077,	found	247.1105.	
(S)-2-Amino-6-(3-carbamoylphenyl)hexanoic	acid	(28)	
Compound	26	(100	mg,	0.46	mmol)	was	reduced	following	the	
procedure	described	 for	compound	18.	The	 intermediate	was	
deprotected	 in	 TFA/DCM	 (1:1,	 4	 mL)	 for	 2	 hours	 at	 room	
temperature.	 The	mixture	was	 concentrated	 and	 the	product	
was	purified	by	preparative	HPLC	affording	compound	28	as	a	
white	 powder.	 1H	 NMR	 (400	 MHz,	 DMSO-d6)	 δ	 8.20	 (s,	 2H),	
7.91	(s,	1H),	7.73	–	7.65	(m,	2H),	7.39	–	7.29	(m,	3H),	3.90	(t,	J	=	
5.8	Hz,	1H),	2.62	 (t,	 J	 =	7.6	Hz,	2H),	1.79	 (tt,	 J	 =	14.0,	6.7	Hz,	
2H),	1.61	(p,	J	=	7.5	Hz,	2H),	1.51	–	1.26	(m,	2H).	13C	NMR	(101	
MHz,	 DMSO-d6)	 δ	 171.1,	 168.0,	 141.9,	 134.3,	 131.2,	 128.1,	
127.4,	124.9,	51.9,	34.7,	30.3,	29.9,	24.0.	HRMS:	calculated	for	
C13H18N2O3	[M+H]
+:	251.1390,	found	251.1414.	
Methyl-(S)-3-(((4-(tert-butoxy)-3-((tert-butoxycarbonyl)	
amino)-4-oxobutyl)amino)methyl)benzoate	(34)	
To	a	solution	of	methyl	3-formylbenzoate	(140	mg,	0.9	mmol)	
and	 compound	 33	 (220	 mg,	 0.8	 mmol)	 in	 dry	 DCE	 (15	 ml),	
crushed	4Å	molsieves	were	added.	After	2	hours,	Na(OAc)3BH	
(254	mg,	 1.2	mmol)	was	 added	 over	 5	minutes.	 The	mixture	
was	 reacted	 overnight,	 quenched	 with	 saturated	 NaHCO3,	
filtered	 and	 the	 aqueous	 phase	 extracted	 with	 DCM.	 The	
organic	 layers	were	 combined,	washed	with	 Brine,	 dried	 and	
concentrated.	 Purification	 via	 column	 chromatography	
(gradient	of	2.5	to	6%	MeOH	in	DCM)	afforded	compound	34	
(90	mg,	27	%)	as	a	white	powder.	1H	NMR	(400	MHz,	CDCl3)	δ	
7.94	 (s,	 1H),	 7.89	 (d,	 J	 =	 7.7	Hz,	 1H),	 7.52	 (d,	 J	 =	 7.4	Hz,	 1H),	
7.36	(t,	J	=	7.6	Hz,	1H),	5.65	(d,	J	=	7.4	Hz,	1H),	4.34	–	4.10	(m,	
1H),	 3.88	 (s,	 3H),	 3.78	 (s,	 2H),	 2.68	 (t,	 J	 =	 6.6	Hz,	 2H),	 2.06	 –	
1.69	(m,	2H),	1.40	(s,	18H).	13C	NMR	(101	MHz,	CDCl3)	δ	171.9,	
167.1,	 155.7,	 140.5,	 132.9,	 130.3,	 129.3,	 128.6,	 128.4,	 81.8,	
79.5,	53.6,	52.8,	52.1,	45.4,	32.6,	28.4,	28.0.		
(S)-2-Amino-4-((3-carbamoylbenzyl)amino)butanoic	 acid	
(35)	
Compound	 34	 (80	 mg,	 0.19	 mmol)	 was	 first	 deprotected	 in	
TFA:DCM	 (1:2)	 for	 1	 hour	 at	 room	 temperature.	 The	mixture	
was	 concentrated,	 redissolved	 in	 1	mL	MeOH	 and	 1	mL	 25%	
NH3	 (aq)	 and	 crimp	 sealed.	 The	 mixture	 was	 reacted	 for	 4	
hours	 at	 130°C	 in	 the	 microwave.	 The	 mixture	 was	
concentrated	 and	 purified	 by	 preparative	 HPLC	 affording	
compound	34	 as	 a	white	powder.	 1H	NMR	 (400	MHz,	DMSO-
d6)	δ	8.06	–	8.01	(m,	2H),	7.92	(d,	J	=	7.8	Hz,	1H),	7.62	(d,	J	=	7.7	
Hz,	1H),	7.52	(t,	J	=	7.6	Hz,	1H),	7.46	(s,	1H),	4.23	(s,	2H),	4.12	–	
3.96	(m,	1H),	3.24	–	2.96	(m,	2H),	2.26	–	2.01	(m,	2H).	13C	NMR	
(101	 MHz,	 DMSO-d6)	 δ	 170.2,	 167.4,	 134.7,	 132.6,	 132.0,	
129.5,	 128.6,	 127.7,	 50.0,	 49.7,	 43.3,	 26.5.	 HRMS:	 calculated	
for	C12H17N3O3	[M+H]
+:	252.1343,	found	252.1360.	
Methyl	3-((acetylthio)methyl)benzoate	(38)	
Following	 a	 procedure	 described	 in	 literature19,	 methyl-3-
bromomethylbenzoate	 (1.15	 g,	 5.0	 mmol)	 was	 reacted	 with	
silica-gel	 supported	 potassium	 thioacetate	 (7.5	 g,	 1	 mmol/g,	
7.5	 mmol)	 in	 toluene	 (20	 mL).	 After	 1	 hour	 at	 room	
temperature,	 the	 mixture	 was	 filtered	 and	 concentrated	
yielding	compound	38	as	a	slightly	yellow	oil	(1.01	g,	91%).	The	
compound	had	NMR	spectra	and	mass	spectra	consistent	with	
the	assigned	structures25.	
Methyl	3-(mercaptomethyl)benzoate	(39)	
Following	a	procedure	described	 in	 literature26,	compound	38	
(224	 mg,	 1.0	 mmol)	 was	 deacetylated	 using	 potassium	
carbonate	 (350	 mg,	 2.5	 mmol)	 in	 methanol	 (15	 mL).	 After	
stirring	 for	 2	 hours	 at	 room	 temperature,	 the	 reaction	 was	
quenched	using	 0.1	M	HCl	 to	 pH	2.5,	 diluted	with	water	 and	
extracted	 with	 DCM.	 The	 organic	 phase	 was	 washed	 with	
Brine,	dried	and	concentrated	yielding	compound	39	(170	mg,	
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93%).	 The	 compound	 had	 NMR	 spectra	 and	 mass	 spectra	
consistent	with	the	assigned	structures27.	
Methyl	 (S)-3-(((4-(tert-butoxy)-3-((tert-butoxycarbonyl)-
amino)-4-oxobutyl)thio)methyl)benzoate	(40)	
To	a	solution	of	 thiol	39	 (170	mg,	0.9	mmol)	and	bromide	36	
(270	mg,	0.8	mmol)	in	dry	DMF	(10	mL),	potassium	carbonate	
(350	 mg,	 2.5	 mmol)	 was	 added.	 After	 2	 hours,	 at	 room	
temperature,	 TLC	 shows	 completion	 and	 the	 mixture	 was	
concentrated,	redissolved	in	DCM	and	washed	with	water.	The	
aqueous	 phase	 was	 extracted	 with	 DCM,	 the	 organic	 layers	
were	 combined,	 washed	with	 Brine,	 dried	 and	 concentrated.	
Purification	via	column	chromatography	 (hexanes/	EtOAc	8:1)	
afforded	compound	40	 (245	mg,	60	%)	as	a	clear	oil.	 1H	NMR	
(400	MHz,	CDCl3)	δ	7.94	(s,	1H),	7.88	(d,	J	=	7.8	Hz,	1H),	7.49	(d,	
J	=	7.7	Hz,	1H),	7.35	(t,	J	=	7.7	Hz,	1H),	5.08	(d,	J	=	7.5	Hz,	1H),	
4.23	–	4.17	(m,	1H),	3.88	(s,	3H),	3.71	(s,	2H),	2.45	–	2.35	(m,	
2H),	 2.08	 –	 1.74	 (m,	 2H),	 1.39	 (s,	 18H).	 13C	 NMR	 (101	MHz,	
CDCl3)	δ	171.3,	166.8,	155.3,	138.8,	133.4,	130.5,	129.9,	128.7,	
128.4,	82.1,	79.7,	53.4,	52.2,	35.9,	32.8,	28.3,	28.0,	27.2.		
(S)-2-Amino-4-((3-carbamoylbenzyl)thio)butanoic	 acid	
(41)	
Compound	 40	 (100	mg,	 0.23	mmol)	 was	 first	 deprotected	 in	
TFA:DCM	 (1:2)	 for	 1	 hour	 at	 room	 temperature.	 The	mixture	
was	 concentrated,	 redissolved	 in	 1	mL	MeOH	 and	 1	mL	 25%	
NH3	 (aq)	 and	 crimp	 sealed.	 The	 mixture	 was	 reacted	 for	 4	
hours	 at	 130°C	 in	 the	 microwave.	 The	 mixture	 was	
concentrated	 and	 purified	 by	 preparative	 HPLC	 affording	
compound	41	 as	 a	white	 powder.	 1H	NMR	 (400	MHz,	D2O)	 δ	
7.77	 (s,	 1H),	 7.71	 (d,	 J	 =	 8.0	Hz,	 1H),	 7.60	 (d,	 J	 =	 7.8	Hz,	 2H),	
7.49	(t,	J	=	7.7	Hz,	1H),	4.09	(t,	J	=	6.4	Hz,	1H),	3.86	(s,	2H),	2.66	
–	2.55	(m,	2H),	2.29	–	2.04	(m,	2H).	13C	NMR	(101	MHz,	D2O)	δ	
172.6,	 171.9,	 138.8,	 133.0,	 132.8,	 129.1,	 127.7,	 126.2,	 51.9,	
34.5,	 29.3,	 25.8.	 HRMS:	 calculated	 for	 C12H16N2O3	 [M+H]
+:	
269.0954,	found	269.0955.	
Methyl	 3-(((((3aR,4R,6R,6aR)-6-(6-amino-9H-purin-9-yl)-
2,2-dimethyltetrahydrofuro[3,4-d][1,3]-dioxol-4-yl)methyl)-
((S)-4-(tert-butoxy)-3-((tert-butoxycarbonyl)amino)-4-oxo-
butyl)-amino)-methyl)benzoate	(44)	
To	 a	 solution	 of	 compound	 6	 (200	 mg,	 0.44	 mmol)	 and	
aldehyde	43	(126	mg,	0.46	mmol)	in	dry	DCE	(10	ml),	crushed	
4Å	molsieves	were	added.	After	2	hours,	Na(OAc)3BH	(130	mg,	
0.62	 mmol)	 was	 added	 over	 5	 minutes.	 The	 mixture	 was	
reacted	 overnight,	 quenched	with	 saturated	NaHCO3,	 filtered	
and	the	aqueous	phase	was	extracted	with	DCM.	The	organic	
layers	 were	 combined,	 washed	 with	 Brine,	 dried	 and	
concentrated.	 Purification	 via	 column	 chromatography	
(gradient	of	2.5	to	7.5%	MeOH	in	DCM)	afforded	compound	44	
(156	mg,	53	%)	as	a	white	powder.	1H	NMR	(400	MHz,	CDCl3)	δ	
8.20	(s,	1H),	7.89-7.87	(m,	2H),	7.83	(br	s,	1H),	7.49	(d,	J	=	7.7	
Hz,	1H),	7.30	(t,	J	=	7.9	Hz,	1H),	6.02	(br	s,	1H),	5.73	(br	s,	1H),	
5.41-5.36	 (br	m,	 2H),	 4.90	 (dd,	 J	=	3.5,	 6.4	Hz,	 2H),	 4.38-4.34	
(m,	1H),	4.17-4.16	(m,	1H),	3.91	(s,	3H),	3.70	(d,	J	=	13.7	Hz,	1H	
),	 3.54	 (dd,	 J	=	13.7	Hz,	 1H),	 2.81-2.76	 (m,	2H),	 2.70-2.61	 (m,	
2H),	 2.55-2.48	 (m,	 2H),	 2.01-1.97	 (m,	 2H),	 1.80-1.76	 (m,	 1H),	
1.60	 (s,	3H),	1.43	 (s,	9H),	1.40	 (s,	9H),	1.37	 (s,	3H),	1.26	 (br	s,	
1H).	 3C	 NMR	 (101	MHz,	 CDCl3)	 δ	 171.7,	 167.1,	 155.6,	 153.1,	
149.3,	 139.3,	 133.6,	 130.1,	 130.0,	 128.5,	 128.4,	 120.5,	 114.5,	
90.9,	 85.5,	 83.9,	 83.5,	 81.8,	 79.6,	 58.8,	 55.8,	 52.9,	 52.2,	 50.7,	
29.7,	 28.5,	 28.1,	 27.3,	 25.5.	 HRMS:	 calculated	 for	 C35H49N7O9	
[M+H]+	712.3365,	found	712.3371.	
(S)-2-Amino-4-((((2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-
3,4-dihydroxytetrahydrofuran-2-yl)methyl)(3-carbamoyl-
benzyl)-amino)butanoic	acid	(45)	
Compound	 44	 (80	 mg,	 0.19	 mmol)	 was	 first	 deprotected	 in	
TFA:DCM	 (1:2)	 for	 1	 hour	 at	 room	 temperature.	 The	mixture	
was	 concentrated,	 redissolved	 in	 1	mL	MeOH	 and	 1	mL	 25%	
NH3	 (aq)	 and	 crimp	 sealed.	 The	 mixture	 was	 reacted	 for	 4	
hours	 at	 130°C	 in	 the	 microwave.	 The	 mixture	 was	
concentrated	 and	 purified	 by	 preparative	 HPLC	 affording	
compound	45	as	a	white	powder.	1H	NMR	(400	MHz,	(D2O):		δ	
8.27	(s,	1H),	8.18	(s,	1H),	7.77	–	7.57	(m,	3H),	7.42	(t,	J	=	7.7	Hz,	
1H),	6.10	(s,	1H),	4.66	(dd,	J	=	5.3,	2.9	Hz,	1H),	4.62	–	4.43	(m,	
4H),	3.87	(dd,	J	=	9.2,	3.7	Hz,	1H),	3.73	–	3.61	(m,	3H),	2.58	–	
2.38	 (m,	 1H),	 2.38	 –	 2.23	 (m,	 1H).	 13C	 NMR	 (101	MHz,	 D2O)	
δ171.7,	167.1,	155.6,	153.1,	149.3,	139.3,	133.6,	130.1,	130.0,	
128.5,	 128.4,	 120.5,	 114.5,	 90.9,	 85.5,	 83.9,	 83.5,	 81.8,	 79.6,	
58.8,	55.8,	52.9,	52.2,	50.7,	29.7,	28.5,	28.1,	27.3,	25.5.	HRMS:	
calculated	for	C22H28N8O6	[M+H]
+	501.2205;	found	501.2223.	
	
Enzymatic	activity	assay	
The	enzyme	was	cloned,	expressed	and	purified	as	previously	
described.15	 Purity	 of	 the	 enzyme	 was	 confirmed	 using	
SDS−PAGE	 with	 Coomassie	 blue	 staining	 (see	 supplemental	
figure	S1)	and	NNMT	 identity	was	confirmed	using	SDS−PAGE	
and	Western	blotting.	Catalytic	activity	of	recombinant	protein	
was	evaluated	as	previously	reported15	with	1	unit	of	enzyme	
activity	representing	the	formation	of	1	nmol	of	MNA	per	hour	
of	incubation	at	37	°C.	The	homogeneous	recombinant	NNMT	
specific	 activity	 was	 10260	 units/mg	 of	 protein	 at	 a	 protein	
concentration	 of	 1.1	 mg/mL.	 NNMT	 was	 used	 at	 a	 final	
concentration	of	 150	nM	 in	 a	mixture	 containing	50	mM	Tris	
Buffer	 (pH	 8.6)	 and	 1	 mM	 DTT.	 	 The	 compounds	 were	
incubated	 with	 the	 enzyme	 at	 room	 temperature	 for	 10	
minutes	before	initiating	the	reaction	with	a	mixture	of	NA	and	
AdoMet	at	their	KM	values	of	200	µM	and	8.5	µM	respectively.	
The	 concentration	 of	 inhibitor	 ranged	 from	 1	 µM	 to	 1	 mM	
(DMSO	was	kept	below	5%	final	concentration).	The	formation	
of	MNA	was	measured	after	30	minutes	at	37°C.	The	reaction	
was	 quenched	 by	 addition	 of	 15	 µL	 sample	 to	 70	 µL	
acetonitrile	containing	5	µM	deutero-methylated	nicotinamide	
as	 internal	 standard.	 The	 enzymatic	 activity	 assays	 were	
performed	 using	 UHP-HILIC-MS	 as	 previously	 described	 with	
minor	modifications.16	 UHP-HILIC-MS	 analysis	 was	 performed	
using	 a	 1290	 Infinity	 UHPLC	 system	 (Agilent	 Technologies,	
Waldbronn,	 BW,	 Germany)	 consisting	 of	 a	 binary	 pump,	 an	
autosampler	 and	 a	 temperature	 controlled	 column	
department	at	65°C	with	a	Waters	(Milford,	MA,	USA)	acquity	
UPLC	BEH	amide	1.7	µm	3.0x100	mm	HILIC	column	coupled	to	
a	Q-TOF	 II	mass	 spectrometer	with	an	electrospray	 ionization	
source	 and	 liquid	 chromatography	 sprayer	 from	 Bruker	
Daltonics	(Bremen,	HB,	Germany),	operated	 in	positive	mode.	
The	 analytes	 were	 isocratically	 eluted	 using	 20%	 water	
containing	 300	 µM	 formic	 acid	 and	 550	 µM	NH4OH	 (pH	 9.2)	
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and	80%	acetonitrile	with	a	flow-rate	of	0.6	mL/min	and	a	run-
time	of	2.6	minutes.	The	 injection	volume	was	10	µL	and	 the	
spectra	 sample	 rate	 was	 0.8	 Hz.	 For	 the	 analysis	 of	 the	
inhibitory	activity	of	MNA,	4MeNA	was	used	as	a	substrate	at	
its	KM	concentration	of	400	µM.
16	The	other	parameters	in	the	
assay	 were	 kept	 the	 same.	 The	 enzymatic	 activity	 was	
determined	 by	 measurement	 of	 the	 formation	 of	 MNA.	 The	
results	were	normalized	with	the	“no	 inhibitor”	control	set	at	
100%	activity.	The	“no	inhibitor”	controls	were	independently	
performed	 for	 each	 IC50	 determination.	 The	 measured	
activities	were	plotted	as	a	function	of	inhibitor	concentration.	
The	“no	inhibitor”	control	was	plotted	at	0.1	µM,	10-fold	lower	
than	 the	 lowest	 concentration	 measured.	 Plotting	 the	 “no	
inhibitor”	control	at	0.01	µM	or	0.001	µM	had	no	effect	on	the	
curve	fit	or	the	IC50	data	generated.	
The	data	was	fitted	using	non-linear	regression	analysis	of	the	
Sigmoidal	 dose-response	 curve	 generated	 using	 normalized	
data	and	a	variable	slope	following	equation	1;	
	
Y= !""(!!!"((!"#$%!"!!)∗!"##$#%&')))	 Equation	[1]	
where	Y	=	percent	activity,	X	=	the	logarithmic	concentration	of	
the	compound	and	Hill	Slope	=	slope	factor	or	Hill	coefficient.	
The	 IC50	value	was	determined	by	the	concentration	resulting	
in	 a	 half-maximal	 percent	 activity.	 Values	 are	 reported	 along	
with	standard	errors	of	the	mean	(S.E.M.,	calculated	using	the	
symmetrical	 CI	 function	 in	 Graphpad	 Prism	 6)	 indicating	 the	
precision	of	the	mean	values	obtained.	
	
Modelling	studies	
Compound	45	was	built	 in	Yasara	version	16.9.2328,	based	on	
the	AdoHcy	and	NA	structure	in	complex	with	NNMT	(PDB-ID:	
3ROD).15	 The	model	was	 energy	minimized	with	 the	 steepest	
descent	 method	 using	 the	 Amber14	 forcefield29,	 before	
analysing	the	hydrogen	bond	interactions	with	Yasara	(Fig.	4).		
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